Trump DOJ Moves to Halt 2 Abortion Pill Lawsuits Amid FDA Review
The Trump administration is asking federal courts to halt key lawsuits targeting the abortion pill, delaying decisions that could reshape access nationwide.
The move centers on multiple cases filed by Republican-led states seeking to roll back expanded access to mifepristone, including telehealth prescriptions and mail delivery.
According to OSV News and News From The States, the Department of Justice has formally requested judges either pause proceedings or dismiss the cases entirely until the Food and Drug Administration completes an ongoing review of the drug.
That review has no clear timeline, raising questions about whether the legal strategy is a delay tactic or part of a broader policy shift.
“The court should either stay this case… or dismiss it,” DOJ lawyers argued in one filing.
Subscribe free for daily political analysis they won’t broadcast. Join 115K+ readers →
The stakes are high because mifepristone is used in more than half of U.S. abortions, and several lawsuits aim to reinstate stricter rules that would limit access across multiple states.
At the same time, the administration’s position has created tension with both sides, with anti-abortion advocates criticizing delays while legal groups argue the DOJ is not actively defending access either.
What happens next depends largely on the FDA review, which could take months and determine whether courts move forward or remain stalled.
For now, the legal fight over abortion pills is paused in uncertainty.
Subscribe free for daily political analysis they won’t broadcast. Join 115K+ readers →